Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular Lymphoma

NCT04156828 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04156828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04156828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular Lymphoma
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2020
Completion date
June 8, 2023
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

grade 3b follicular lymphoma, non-hodgkin's lymphoma, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, refractory diffuse large b-cell lymphoma